S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH

Size: px
Start display at page:

Download "S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH"

Transcription

1 :30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome and introduction S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH 10:45-12:15 Standards in NSCLC in 2018 Sala B Moderation: M. Garassino, S. Rauh ; Milan, IT, Esch Sur Alzette, LU 10:45-11:05 Standards of care in locally advanced, unresectable NSCLC M. Garassino, Milan, IT 11:05-11:10 Case presentation: Locally advanced unresectable NSCLC - immuno following radio-chemo 11:10-11:25 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 11:25-11:30 Case presentation: Adjuvant treatment oncogene-addicted NSCLC anti EGFR / same for ALK, Ros, etc. 11:30-11:45 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 11:45-11:50 Case presentation: Metastatic oncogene addicted, PD-L1 post: treatment schedule? 11:50-12:05 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 12:05-12:15 Conclusion and future outlook M. Garassino, Milan, IT 12:15-13:15 Lunch Sala B

2 13:15-13:45 Keynote lecture Sala B Moderation: 13:15-13:45 Immunotherapy in 2018: Hope, hype or breakthrough: An overview of use and benefit in current knowledge 13:45-15:15 Standards in melanoma in 2018 Sala B Moderation: R. Curca, O. Michielin ; Alba Iulia, RO, Lausanne, CH 13:45-13:50 Introduction and overview of the most relevant, practice-changing abstracts in 2017 R. Curca, Alba Iulia, RO 13:50-14:10 Standards of care in metastatic melanoma O. Michielin, Lausanne, CH 14:10-14:20 Case presentation: BRAF WT patient R. Curca, Alba Iulia, RO 14:20-14:40 Discussion R. Curca 1, O. Michielin 2 ; 1 Alba Iulia, RO, 2 Lausanne, CH 14:40-14:50 Case presentation: BRAF mutant patient R. Curca, Alba Iulia, RO 14:50-15:10 Discussion R. Curca 1, O. Michielin 2 ; 1 Alba Iulia, RO, 2 Lausanne, CH 15:10-15:15 Conclusions and future outlook O. Michielin, Lausanne, CH 15:15-15:45 Coffee break Sala B

3 15:45-17:30 Standards in colorectal cancer in 2018 Sala B Moderation: M. Karamouzis, D. Arnold ; Kolonaki, Athens/GR, Hamburg, DE 15:45-15:55 Introduction M. Karamouzis 1, D. Arnold 2 ; 1 Kolonaki, GR, 2 Hamburg, DE 15:55-16:20 Are we ready to change the duration of adjuvant chemotherapy in 2018? Adjuvant treatment of rectal cancer what s new in 2018? D. Arnold, Hamburg, DE 16:20-16:45 Metastatic colorectal cancer - what s new in 2018? M. Karamouzis, Kolonaki, GR 16:45-16:50 Case presentation: Early stage disease M. Karamouzis, Kolonaki, GR 16:50-17:05 Discussion D. Arnold, Hamburg, DE 17:05-17:10 Case presentation: Metastatic stage disease D. Arnold, Hamburg, DE 17:10-17:25 Discussion M. Karamouzis, Kolonaki, Athens/GR 17:25-17:30 Conclusions and future outlook D. Arnold 1, M. Karamouzis 2 ; 1 Hamburg, DE, 2 Kolonaki, Athens/GR

4 17:30-19:00 Standards in non-hodgkin's lymphoma in 2018 Sala B Moderation: R. Eckert, M. Ghielmini ; Esslingen, DE, Bellinzona, CH 17:30-17:35 Introduction R. Eckert, Esslingen, DE 17:35-17:55 Non-Hodgkin Lymphoma diagnostics and treatment: State of the art in 2018 M. Ghielmini, Bellinzona, CH 17:55-18:15 Case: Beat it hard: Aggressive lymphoma - Diffuse large B cell lymphoma with high IPI. Discussion with audience and take home message(s) R. Eckert 1, M. Ghielmini 2 ; 1 Esslingen, DE, 2 Bellinzona, CH 18:15-18:35 Case: How tough do you need to get?: Indolent lymphoma - Follicular lymphoma, advanced stage. Discussion with audience and take-home message(s) R. Eckert 1, M. Ghielmini 2 ; 1 Esslingen, DE, 2 Bellinzona, CH 18:35-18:50 Case presentation: Take your time: MALT lymphoma of the stomach. Discussion with audience and take-home message(s) R. Eckert 1, M. Ghielmini 2 ; 1 Esslingen, DE, 2 Bellinzona, CH 18:50-19:00 Conclusions and future outlook M. Ghielmini, Bellinzona, CH

5 09:00-10:30 Standards in locally advanced, non-metastatic upper GI cancers (Gastroesophageal) in 2018 Sala B Moderation: G. Lakatos, M. Ducreux ; Budapest, HU, Villejuif, CEDEX/FR 09:00-09:05 Introduction G. Lakatos, Budapest, HU 09:05-09:25 Standards of care in upper GI cancers M. Ducreux, Villejuif, CEDEX/FR 09:25-09:35 Case presentation: Locally advanced oesophageal cancer G. Lakatos, Budapest, HU 09:35-09:55 Discussion G. Lakatos 1, M. Ducreux 2 ; 1 Budapest, HU, 2 Villejuif, CEDEX/FR 09:55-10:05 Case presentation: Locally advanced gastric cancer G. Lakatos, Budapest, HU 10:05-10:25 Discussion G. Lakatos 1, M. Ducreux 2 ; 1 Budapest, HU, 2 Villejuif, CEDEX/FR 10:25-10:30 Conclusions and future outlook M. Ducreux, Villejuif, CEDEX/FR 10:30-11:00 Coffee break Sala B

6 11:00-12:30 Standards in metastatic prostate cancer in 2018 Sala B Moderation: A. Froebe, M. De Santis ; Zagreb, HR, Berlin, DE 11:00-11:05 Introduction A. Froebe, Zagreb, HR 11:05-11:25 Standards of care in metastatic prostate cancer M. De Santis, Berlin, DE 11:25-11:35 Case presentation: Metastatic prostate cancer upon initial diagnosis: CHAARTED, etc. A. Froebe, Zagreb, HR 11:35-11:55 Discussion A. Froebe 1, M. De Santis 2 ; 1 Zagreb, HR, 2 Berlin, DE 11:55-12:05 Case presentation: CRPC incl. therapeutic use of isotopes in metastatic prostate cancer A. Froebe, Zagreb, HR 12:05-12:25 Discussion A. Froebe 1, M. De Santis 2 ; 1 Zagreb, HR, 2 Berlin, DE 12:25-12:30 Conclusions and future outlook M. De Santis, Berlin, DE 12:30-13:30 Lunch Sala B 13:30-14:00 Keynote lecture: San Salvatore Foundation Ceremony Sala B Moderation: R.A. Stahel, S. Rauh ; Zürich, CH, Esch Sur Alzette, LU 13:30-13:40 San Salvatore Foundation introduction and award presentation L. Butti 1, R.A. Stahel 2 ; 1 Lugano, CH, 2 Zürich, CH 13:40-14:00 Keynote Award Lecture F. André, Villejuif, CEDEX/FR

7 14:00-15:30 Standards in bladder and kidney metastatic cancers in 2018 Sala B Moderation: J. Molitor, Y. Vano; Paris, FR 14:00-14:05 Introduction J. Molitor, Paris, FR 14:05-14:25 Standards of care in bladder and kidney cancer Y. Vano, Paris, FR 14:25-14:35 Case presentation: Immunotherapy in kidney cancer: When? J. Molitor, Paris, FR 14:35-14:55 Discussion J. Molitor, Y. Vano; Paris, FR 14:55-15:05 Case presentation: Second-line treatment for bladder cancer J. Molitor, Paris, FR 15:05-15:25 Discussion Y. Vano, J. Molitor; Paris, FR 15:25-15:30 Conclusions and future outlook Y. Vano, Paris, FR 15:30-16:00 Coffee break Sala B

8 16:00-17:30 Standards in breast cancer in 2018 Sala B Moderation: S. Braga, A. Gennari ; Lisbon, PT, Genova, IT 16:00-16:20 Standards of care in neo-adjuvant /adjuvant breast cancer A. Gennari, Genova, IT 16:20-16:30 Case presentations: An (elderly) patient with HER2 neo adjuvant - adjuvant treatment S. Braga, Lisbon, PT 16:30-16:45 Discussion S. Braga 1, A. Gennari 2 ; 1 Lisbon, PT, 2 Genova, IT 16:45-17:05 Standards of care in metastatic breast cancer, including CDK4 inhibitors and impact on treatment A. Gennari, Genova, IT 17:05-17:15 Case presentation: Who benefits from CDK4 inhibitors? Toxicity issues S. Braga, Lisbon, PT 17:15-17:30 Discussion and future outlook S. Braga 1, A. Gennari 2 ; 1 Lisbon, PT, 2 Genova, IT 17:30-18:00 Workshop: Managing survivorship care Sala B Moderation: 17:30-17:50 ESMO guidelines and survivorship guide 17:50-18:00 Interactive discussion 18:00-19:00 Networking Foyer

9 09:00-10:30 Standards in multiple myeloma in 2018 Sala B Moderation: R. Eckert, J. Harousseau ; Esslingen, DE, Nantes, CEDEX 1/FR 09:00-09:05 Introduction R. Eckert, Esslingen, DE 09:05-09:35 Standards of care in newly diagnosed patients J. Harousseau, Nantes, CEDEX 1/FR 09:35-09:50 Case: Front line treatment in a high risk patient considered suitable for transplant. Discussion with audience R. Eckert 1, J. Harousseau 2 ; 1 Esslingen, DE, 2 Nantes, CEDEX 1/FR 09:50-09:55 Case presentation: Relapsed disease R. Eckert, Esslingen, DE 09:55-10:15 New treatment options for relapsed disease J. Harousseau, Nantes, FR 10:15-10:25 Discussion with audience R. Eckert 1, J. Harousseau 2 ; 1 Esslingen, DE, 2 Nantes, FR 10:25-10:30 Conclusions and future outlook J. Harousseau, Nantes, FR 10:30-11:00 Coffee break Sala B

10 11:00-12:00 Workshop: Management of immunotherapy related toxicity Sala B Moderation: S. Rauh, J. Haanen ; Esch Sur Alzette, LU, Amsterdam, NL 11:00-11:03 Case: Skin toxicity 11:03-11:12 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:12-11:15 Management proposal 11:15-11:18 Case: Hepatotoxicity 11:18-11:27 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:27-11:30 Management proposal 11:30-11:33 Case: Lung toxicity 11:33-11:42 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:42-11:45 Management proposal 11:45-11:48 Case: Endocrine or other 11:48-11:57 Discussion 11:57-12:00 Management proposal

11 12:00-12:30 Workshop: Allergic reactions to chemotherapy- Management including desensibilisation Sala B Moderation: H. van Halteren, Vlissingen, NL 12:00-12:20 The allergologist s contribution to chemo allergies H. van Halteren, Vlissingen, NL 12:20-12:30 Discussion 12:30-12:45 Closing remarks Sala B Moderation: 12:30-12:45 Closing remarks S. Rauh, Esch, LU 12:45-13:15 Lunch Foyer

S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH

S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH 27.04.2018 10:30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome to the Symposium S. Rauh 1, J. Douillard 2 ;

More information

Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT. Moderation: S. Rauh, Esch, LU

Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT. Moderation: S. Rauh, Esch, LU 03-03-2017 13:30-13:45 Opening and welcome Auditorium Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT 13:30-13:45 Welcome to the Conference 13:45-14:15 Keynote lecture Auditorium Moderation: 13:45-14:15

More information

Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES

Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES 08-04-2017 12:45-13:00 Type: Educational session Title: Welcome and Introduction by the Chairs 1 2 1 2 Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES 12:45-13:00 Welcome 13:00-13:15

More information

ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain

ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme 14-19 July 2016, Valencia, Spain Co-chairs: Andrés Cervantes, ES - Nicholas Pavlidis, GR - Susana Banerjee, UK Thursday, 14

More information

CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves Douillard, France

CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves Douillard, France ESMO Preceptorship Programme Colorectal Cancer Multidisciplinary management, standards of care and future perspectives Prague, Czech Republic 6-7 July 2016 CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves

More information

Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception

Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception 02.05.2019 12:00-13:00 Type: Industry Satellite Symposium 12:00-13:00 Type: Industry Satellite Symposium 13:00-13:30 Type: Opening session Title: Welcome reception Exhibition area 13:30-13:45 Type: Opening

More information

:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B

:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B 04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture

More information

Colorectal Cancer Multidisciplinary management, standards of care and future perspectives

Colorectal Cancer Multidisciplinary management, standards of care and future perspectives ESMO Preceptorship Programme Colorectal Cancer Multidisciplinary management, standards of care and future perspectives Prague, Czech Republic 6-7 July 2016 CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves

More information

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018 CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines

More information

CLINICAL ONCOLOGY 3 RD BALKAN AND EASTERN EUROPEAN MASTERCLASS IN May 2013 Dubrovnik, Croatia. Chair: R. Popescu, CH/RO Co-chair: S.

CLINICAL ONCOLOGY 3 RD BALKAN AND EASTERN EUROPEAN MASTERCLASS IN May 2013 Dubrovnik, Croatia. Chair: R. Popescu, CH/RO Co-chair: S. MASTERCLASS 3 RD BALKAN AND EASTERN EUROPEAN MASTERCLASS IN CLINICAL ONCOLOGY 8-12 May 2013 Dubrovnik, Croatia Chair: Co-chair: S. Beslija, BA Aims and objectives This clinically oriented residential educational

More information

Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404

Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404 23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive

More information

PRECEPTORSHIP PROGRAMME

PRECEPTORSHIP PROGRAMME esmo.org PRECEPTORSHIP PROGRAMME Gastrointestinal Tumours Multidisciplinary management, standards of care and future perspectives SINGAPORE 20-22 OCTOBER 2016 Co-Chairs Jean-Yves Douillard, Switzerland

More information

Gastric Cancer Co-Chairs Speakers LEARNING OBJECTIVES

Gastric Cancer Co-Chairs Speakers LEARNING OBJECTIVES ESMO Preceptorship Programme Gastric Cancer Multidisciplinary management, standards of care, therapeutic targets and future perspectives 10-11 June 2016, Prague, Czech Republic Co-Chairs Andres Cervantes

More information

ICLIO National Conference

ICLIO National Conference ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science

More information

Amphithéâtre Bordeaux. Amphithéâtre. C. Massard, Villejuif, CEDEX/FR. N. Rizvi, New York, NY/US

Amphithéâtre Bordeaux. Amphithéâtre. C. Massard, Villejuif, CEDEX/FR. N. Rizvi, New York, NY/US 25.02.2019 08:45-09:30 Opening and welcome + Honorary award Keynote lecture 08:45-08:55 Welcome address 08:55-09:00 Presentation of the TAT 2019 Honorary Award 09:00-09:30 TAT 2018 Honorary Award Keynote

More information

CLINICAL ONCOLOGY March 2012 Ermatingen (Lake Constance), Switzerland

CLINICAL ONCOLOGY March 2012 Ermatingen (Lake Constance), Switzerland MASTERCLASS ERMATINGEN 17/03/12 11 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 17-22 March 2012 Ermatingen (Lake Constance), Switzerland Chairs: N. Pavlidis, GR - R.A. Stahel, CH Scientific Co-ordinators:

More information

ESMO Symposium on Immuno-Oncology Programme book

ESMO Symposium on Immuno-Oncology Programme book IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org

More information

ONCOLOGY NURSING 9 TH ESO-EONS MASTERCLASS IN March 2016 Ermatingen (Lake Constance) Switzerland #16MON

ONCOLOGY NURSING 9 TH ESO-EONS MASTERCLASS IN March 2016 Ermatingen (Lake Constance) Switzerland #16MON MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 9 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 12-17 March 2016 Ermatingen

More information

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March

More information

10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING march 2017 nauen ot Groß Behnitz (Berlin area), Germany. masterclass

10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING march 2017 nauen ot Groß Behnitz (Berlin area), Germany. masterclass 10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 25-30 march 2017 nauen ot Groß Behnitz (Berlin area), Germany Chairs: B. Grube, DK - C. Lacerda, PT Coordinator: E. van Muilekom, NL Advisor: masterclass

More information

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Clinical practice guidelines Definition > Systemically developed statements

More information

ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY November 2018 Yerevan, Armenia MASTERCLASS

ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY November 2018 Yerevan, Armenia MASTERCLASS ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY 10-13 November 2018 Yerevan, Armenia Chairs: G. Curigliano, IT F. Peccatori, IT Host Chair: G. Tamamyan, AM Held in collaboration with MASTERCLASS AIMS AND OBJECTIVES

More information

ROOM: CONRAD + ARNOLD. ROOM: CONRAD + ARNOLD Focus on ESO, ESMO and EONS Nicholas Pavlidis, Rolf Stahel,

ROOM: CONRAD + ARNOLD. ROOM: CONRAD + ARNOLD Focus on ESO, ESMO and EONS Nicholas Pavlidis, Rolf Stahel, 17h ESO-ESMO Masterclass in Clinical Oncology 24-29 March 2018, Berlin, Germany In collaboration with the Flims Alumni Club Chair: Nicholas Pavlidis, GR and Rolf A. Stahel, CH Scientific Advisors: R. Popescu,

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

New Developments in Cancer Treatment. Ian Rabinowitz MD

New Developments in Cancer Treatment. Ian Rabinowitz MD New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis

More information

Programme - Friday, 7 September

Programme - Friday, 7 September Programme - 15th Meeting of the EAU Robotic Urology Section Room: Auditorium Actual programme might be subject to change due to live surgery Live broadcasts from Institut Paoli-Calmettes and Hôpital Nord,

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates. 6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes

More information

Outcomes Report: Accountability Measures and Quality Improvements

Outcomes Report: Accountability Measures and Quality Improvements Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.

More information

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

October 17 20, 2018 New York City. An International Congress on Lymphoma, Myeloma, and Leukemia Disorders

October 17 20, 2018 New York City. An International Congress on Lymphoma, Myeloma, and Leukemia Disorders An International Congress on Lymphoma, Myeloma, and Leukemia Disorders NEW DAY! New Approaches in Acute Leukemias and Hematologic Malignancies Wednesday, October 17 October 17 20, 2018 New York City lymphomaandmyeloma.com

More information

MEDICAL ONCOLOGY ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN. 27 June - 2 July 2014 Brdo, Slovenia. Chairs: T. Cufer, SI R.

MEDICAL ONCOLOGY ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN. 27 June - 2 July 2014 Brdo, Slovenia. Chairs: T. Cufer, SI R. Flyer MMO_(4 Mar)_screen 04.04.2014 09:33 Pagina 3 MASTERCLASS ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 27 June - 2 July 2014 Brdo, Slovenia Chairs: R. Herrmann, CH This

More information

Studienverzeichnis Medizinische Onkologie

Studienverzeichnis Medizinische Onkologie Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen

More information

Macmillan Publications

Macmillan Publications S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer

More information

National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)

National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2) National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda

More information

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019 MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments

More information

High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT)

High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT) Friday, 8 June 2018 EAU Update on Bladder Cancer (BCa18) Challenging your knowledge of the EAU Guidelines 8-9 June 2018, Munich, Germany Steering committee: F. Montorsi, H. Van Poppel and M. Wirth Scientific

More information

W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES

W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES 10.04.2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture

More information

VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH

VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY 8-9 April 2011 Viareggio, Italy Chair: M. Aapro, CH Dear Colleagues, The European School of Oncology is

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

First SAMO Workshop on Multidisciplinary Approaches to Gastrointestinal Tumors

First SAMO Workshop on Multidisciplinary Approaches to Gastrointestinal Tumors First SAMO Workshop on Multidisciplinary Approaches to Gastrointestinal Tumors 25 th and 26 th April 2008 Hotel Hermitage, Lucerne Continuous Education SGMO/SSMO 10 credits (category B) SRO 10 credits

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

oncology For 9 th eso-esmo course on July 2012 ioannina, Greece

oncology For 9 th eso-esmo course on July 2012 ioannina, Greece ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA ioannina 21/07/12 9 th eso-esmo course on oncology For medical students 21-27 July 2012 ioannina, Greece chair: N. Pavlidis, GR core faculty: R.A. Audisio, UK

More information

Progress in Tumor Research

Progress in Tumor Research Immuno-Oncology Progress in Tumor Research Vol. 42 Series Editors Rolf A. Stahel Zurich Solange Peters Lausanne Immuno-Oncology Volume Editors Olivier Michielin Lausanne George Coukos Lausanne 8 figures,

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda

More information

SCIENTIFIC TIMETABLE SIOP 2015

SCIENTIFIC TIMETABLE SIOP 2015 SCIENTIFIC TIMETABLE SIOP 2015 September, 2015 WEDNESDAY, 7 TH OCTOBER 2015 / DAY 2 1.43 09:30 SIOP Committee 12:00 SIOP Essential Drugs Working 13:00 SIOP Work (Open) 14:00 Nurse Researchers 16:00 17:00

More information

ESOU programme Prostate cancer screening: Why screening programme should not be adopted in > 65 A. Heidenreich, Aachen (DE)

ESOU programme Prostate cancer screening: Why screening programme should not be adopted in > 65 A. Heidenreich, Aachen (DE) Friday, 17 January 08.30-08.40 Welcome M. Babjuk, Prague (CZ) M. Brausi, Modena (IT) 08.40-09.00 Opening address ESOU programme 09.00-11.00 Prostate cancer I: Screening, diagnosis, staging and treatment

More information

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda

More information

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future

More information

4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2018 Mexico City, Mexico LATIN-AMERICA PROGRAMME

4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2018 Mexico City, Mexico LATIN-AMERICA PROGRAMME 4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 18-22 April 2018 Mexico City, Mexico Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.

More information

JY Douillard MD, PhD Professor of Medical Oncology

JY Douillard MD, PhD Professor of Medical Oncology Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard

More information

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME 3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 26-30 April 2017 San Jose, Costa Rica Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.

More information

Identifying and counting people living with treatable but not curable cancer

Identifying and counting people living with treatable but not curable cancer Identifying and counting people living with treatable but not curable cancer Rachel White Joanna Pethick, Archie Macnair, Gregory Fallica, Jennifer Than and Jane Maher September 2018 Who are the people

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes

More information

JY Douillard MD, PhD Professor of Medical Oncology

JY Douillard MD, PhD Professor of Medical Oncology ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer

More information

New Developments in Cancer Treatment. Dulcinea Quintana, MD

New Developments in Cancer Treatment. Dulcinea Quintana, MD New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4

More information

Keytruda (pembrolizumab)

Keytruda (pembrolizumab) Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The

More information

ONCOLOGY NURSING 6 TH ESO-EONS MASTERCLASS IN March 2013 Ermatingen (Lake Constance) Switzerland MASTERCLASS

ONCOLOGY NURSING 6 TH ESO-EONS MASTERCLASS IN March 2013 Ermatingen (Lake Constance) Switzerland MASTERCLASS MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 6 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 16-21 March 2013 Ermatingen

More information

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R) Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed

More information

Immunotherapy Treatment Developments in Medical Oncology

Immunotherapy Treatment Developments in Medical Oncology Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired

More information

Pembrolizumab in combination with epacadostat for unresectable or metastatic melanoma

Pembrolizumab in combination with epacadostat for unresectable or metastatic melanoma NIHR Innovation Observatory Evidence Briefing: January 2018 Pembrolizumab in combination with epacadostat for unresectable or metastatic melanoma NIHRIO (HSRIC) ID: 7812 NICE ID: 9396 LAY SUMMARY Melanoma

More information

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million 31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million cancer cases Adult patients (age 15+) 45 major cancer sites

More information

3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany

3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany 3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany Scientific Program Thursday, 18th April 2013 HR Thursday, 18th April 08:00 Breakfast Symposia 09:00 Registration

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the

More information

October 6-7, 2017 Marseille, France

October 6-7, 2017 Marseille, France Program Chairs M. Ahluwalia (US) E. Le Rhun (FR) P. Métellus (FR) M. Weller (CH) Scientific Committee M. Ahluwalia (US) Z. Ram (IL) F. Dhermain (FR) R. Soffietti (IT) E. Le Rhun (FR) M. Weller (CH) P.

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

CANCER BIOLOGY FOR CLINICIANS

CANCER BIOLOGY FOR CLINICIANS www.esmo.org/events CANCER BIOLOGY FOR CLINICIANS Symposium Nice, France 26-27 November 2010 Program Book 1 Organization and contacts Organization, Program, Registration ESMO Head Office c/o ESMO Congress

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016 Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC 20037 October 19-21, 2016 Wednesday, October 19, 2016 7:30 8:30 AM Registration

More information

Outcomes Report: Accountability Measures and Quality Improvements

Outcomes Report: Accountability Measures and Quality Improvements Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited

More information

TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)

TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital) Legend: Keynote Educational Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite SIOPe GA SIOP ABM Late Breaker Session Networking

More information

6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R.

6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R. MASTERCLASS 6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY Held with the support of 11-16 June 2016 Berlin, Germany Chairs: A. Eggert, DE B. Morland, UK R. Riccardi, IT INTRODUCTION ESO and SIOP-Europe

More information

Program Schedule Clinical Multidisciplinary Hematology & Oncology: The 16 th Annual Review

Program Schedule Clinical Multidisciplinary Hematology & Oncology: The 16 th Annual Review Program Schedule Clinical Multidisciplinary Hematology & Oncology: The 16 th Annual Review Friday, February 15, 2019 6:45 a.m. Registration, Breakfast and Exhibits 7:30 a.m. Welcome and Introductions SESSION

More information

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram

More information

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by: ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.

More information

Highlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer

Highlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME 3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 26-30 April 2017 San Jose, Costa Rica Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.

More information

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented

More information

Gastrointestinal Oncology

Gastrointestinal Oncology 2 nd MD ANDERSON INTERNATIONAL MEETING IN Gastrointestinal Oncology CURRENT PRACTICE AND CONTROVERSIES in the Era of Personalized Medicine e Madrid, 13 th -15 th November, 2019 SCIENTIFIC PROGRAM Meeting

More information

SCOTTISH ONCOLOGY SUMMIT Double Tree by Hilton, Dunblane Hydro, Dunblane 1 st - 2 nd September 2017

SCOTTISH ONCOLOGY SUMMIT Double Tree by Hilton, Dunblane Hydro, Dunblane 1 st - 2 nd September 2017 Friday 1 st September 1300h 1400h Lunch (arrival, registration at conference foyer, coffee and sponsors exhibition) 1400h 1420h Prof Robert Jones Welcome/Announcements 1430h 1600h Parallel sessions: Lung

More information

Focus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct

Focus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley

More information

2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO

2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO 2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION KEYTRUDA has been issued marketing authorization with conditions for the following patients, pending the results of

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date: Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES

CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES ESMO Preceptorship GI Tumours Singapore 20-22 nd October CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES Professor. J-Y. Douillard MD PhD ESMO Chief Medical Officer CLINICAL PRACTICE GUIDELINES

More information

Imaging evaluation of response in NSCLC R. Efthymiadou. Minimal thoracic surgery-maximum efficacy. What new in 2018 K. Iliadis

Imaging evaluation of response in NSCLC R. Efthymiadou. Minimal thoracic surgery-maximum efficacy. What new in 2018 K. Iliadis I N T Lung Cancer Seminar E R N A T I O N A L friday September 14, 2018 14.00-15.00 Registration opens 15.00-15.30 LECTURE I Chairpersons: V. Iordanoglou, Ch. Marinou Smoking and lung cancer epidemiology

More information

ONCOLOGY NURSING March 2012 Ermatingen (Lake Constance), Switzerland

ONCOLOGY NURSING March 2012 Ermatingen (Lake Constance), Switzerland MASTERCLASS ERMATINGEN 17/03/12 5 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 17-22 March 2012 Ermatingen (Lake Constance), Switzerland Chairs: A. Margulies, CH - S. Faithfull, UK Scientific Coordinator:

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3

Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high

More information

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu. R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking

More information

Wojciech Nowak, Rector of the Jagiellonian University Medical College, Kraków (PL)

Wojciech Nowak, Rector of the Jagiellonian University Medical College, Kraków (PL) Chairs Jakub Kenig, Jagiellonian University Medical College, Kraków (PL) Riccardo A. Audisio, Whiston Hospital, University of Liverpool, Liverpool, (UK) Tomasz Grodzicki, Jagiellonian University Medical

More information